SCHEMBL19690236

SCHEMBL19690236

N#Cc1ccc(N2CC(O)(c3ccc(O)cc3Cl)C2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 3/20 0.41
CHRM4 P08173 1/20 0.38
PANK3 Q9H999 4/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ITGAL P20701 1/20 0.37
PPARG P37231 2/20 0.37
NR1H4 Q96RI1 3/20 0.37
KCNJ1 P48048 1/20 0.36
GPR39 O43194 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
FLT3 P36888 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
CYP19A1 P11511 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32678085 1.00 SMO (0.41) SMOCHRM4PANK3KDM4EALDH1A1
SCHEMBL32678087 1.00 SMO (0.41) SMOCHRM4PANK3KDM4EALDH1A1
SCHEMBL17843251 0.91 SMO (0.40) SMOCHRM4PANK3PPARGKCNJ1
SCHEMBL19689487 0.84 MALT1 (0.40) CHRM4PANK3PPARGNR1H4CYP19A1
SCHEMBL30064306 0.84 MALT1 (0.40) CHRM4PANK3PPARGNR1H4CYP19A1
SCHEMBL19690321 0.81 NR1H4 (0.40) CHRM4NR1H4KCNJ1CYP19A1
SCHEMBL20749512 0.80 SMO (0.39) SMOCHRM4PANK3PPARGKCNJ1
SCHEMBL19690232 0.80 PANK3 (0.39) SMOPANK3KDM4EALDH1A1L3MBTL1
SCHEMBL32678099 0.80 PANK3 (0.39) SMOPANK3KDM4EALDH1A1L3MBTL1
SCHEMBL32678098 0.80 PANK3 (0.39) SMOPANK3KDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358903-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2025-07-15 US disclosed
US-20220242858-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2022-08-04 US disclosed
EP-3730487-B1 AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS GILEAD SCIENCES INC (US) 2022-04-27 EP disclosed
EP-3730487-B1 AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS GILEAD SCIENCES INC (US) 2022-04-27 EP disclosed
US-11247986-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2022-02-15 US disclosed
US-11247986-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2022-02-15 US disclosed
EP-3730487-A1 AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS Gilead Sciences, Inc. (US) 2020-10-28 EP disclosed
EP-3730487-A1 AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS Gilead Sciences, Inc. (US) 2020-10-28 EP disclosed
US-20190315729-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2019-10-17 US disclosed
US-20190315729-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2019-10-17 US disclosed
US-10329286-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-06-25 US disclosed
US-10329286-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-06-25 US disclosed
EP-3468962-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2019-04-17 EP disclosed
WO-2017218337-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
WO-2017218337-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358903-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 SMO 1107/4885CHRM4 1741/4885PANK3 2412/4885
US-10329286-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 SMO 1107/4885CHRM4 1741/4885PANK3 2412/4885
US-11247986-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 SMO 1107/4885CHRM4 1741/4885PANK3 2412/4885
US-20220242858-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 SMO 1107/4885CHRM4 1741/4885PANK3 2412/4885
US-20190315729-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 SMO 1107/4885CHRM4 1741/4885PANK3 2412/4885
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 SMO 1107/4885CHRM4 1741/4885PANK3 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.